CHMP recommends approval of Johnson & Johnson’s TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapy

{
  "signal_id": "071500c0-0657-7e27-11a6-1925e5acc38f",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-18T11:00:00+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/09/18/3364625/0/en/chmp-recommends-approval-of-johnson-johnson-s-tecvayli-teclistamab-in-relapsed-refractory-multiple-myeloma-after-at-least-one-prior-therapy.html",
    "title": "CHMP recommends approval of Johnson & Johnson’s TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapy",
    "excerpt": "BEERSE, BELGIUM, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson, a worldwide leader in multiple myeloma, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of an indication extension of TECVAYLI ® (teclistamab) for the treatment of adult patients with RRMM who have received at least one prior therapy.",
    "product": "TECVAYLI",
    "summary": "Johnson & Johnson's drug TECVAYLI® (teclistamab) received a recommendation for approval from the European Medicines Agency's CHMP for an extended indication to treat adult patients with relapsed/refractory multiple myeloma who have had at least one prior therapy.",
    "location": "Beerse, Belgium",
    "planning": false,
    "confidence": 0.9,
    "product_data": {
      "name": "TECVAYLI",
      "full_text": "TECVAYLI ® (teclistamab)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-18T11:00:00Z",
    "location_data": [
      {
        "city": "Beerse",
        "state": "Antwerp",
        "region": "Western Europe",
        "country": "Belgium",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Johnson & Johnson, a worldwide leader in multiple myeloma, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of an indication extension of TECVAYLI ® (teclistamab) for the treatment of adult patients with RRMM who have received at least one prior therapy."
  }
}

curl https://signals.autobound.ai/v1/signals/071500c0-0657-7e27-11a6-1925e5acc38f \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","limit":20}'